ClinicalTrials.gg
Drug

Ivosidenib clinical trials

Also written AG-120 and Tibsovo.

studies test it
55
open now
26
in phase 3
10
first study started
2014

How each study uses ivosidenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the ivosidenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
20 Jul 2018 · TIBSOVO · NDA 211192 (FDA, Drugs@FDA)
European Union
4 May 2023 · Tibsovo · EMEA/H/C/005936 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ivosidenib
30
Ivosidenib Oral Tablet
3

Brand

Tibsovo
12

Development codes

AG-120
21

Studies by the year they started

54 studies that test it; most in 2024 (9); 1 more planned to start later

Studies that test ivosidenib, by start year
YearStudies
20142
20153
20162
20175
20183
20194
20205
20213
20223
20235
20249
20254
20266

By phase

A phase 1/2 study counts in both.

Phase 1
22
Phase 2
27
Phase 3
10
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 13 · Other 42

Institut de Recherches Internationales Servier (8) · Agios Pharmaceuticals, Inc. (5) · Memorial Sloan Kettering Cancer Center (3) · M.D. Anderson Cancer Center (3) · Servier Bio-Innovation LLC (3) · Institute of Hematology & Blood Diseases Hospital, China (3) · National Cancer Institute (NCI) (2) · Servier Affaires Médicales (2)

Often tested with

Tested in the same studies.

Azacitidine (10) · Venetoclax (7) · Enasidenib (6) · Daunorubicin (3) · Idarubicin (3) · Nivolumab (3) · Cytarabine (3) · Gilteritinib (3)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 14, 4 in phase 3

Studies that test ivosidenib, phase 3 first.

Studies

Open first, then newest update. How each study uses ivosidenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 55

See all 55 studies that test ivosidenib →

Given beside what is tested · 5 — ivosidenib is usual care or a partner of the new treatment

Codes

What other systems call ivosidenib · ClinicalTrials.gg INT000950

  • MeSH (NLM) C000627630ivosidenibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) Q2PCN8MAM6IVOSIDENIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2049873One source FDA
  • Wikidata Q27895417ivosidenibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C114383IvosidenibOne source FDA
  • DrugBank DB14568One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.